BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Visiomed Group Limited (VSG) Awarded $40,000 In Grant Funding


10/19/2005 5:09:02 PM

Australia, July 21 2005: Visiomed Group Ltd (ASX:VSG) has been awarded two Business Development and Skills Training Scheme (BDSTS) grants, worth a total of $40,000, from the Innovation and Emerging Industries Branch, Business Development Division, Department Of Industry And Resources, Government of Western Australia.

The BDSTS Grants match up to 50 per cent, or up to $20,000, of the expenditure outlaid for business development activities by the Company.

The first grant, awarded to Visiomed’s wholly-owned subsidiary InfaMed Ltd, will be used in the design simplification and improved assembly of the FunhalerÒ asthma device, aiming to significantly reduce production costs in preparation for the large scale manufacturing of the device for commercialisation in overseas markets.

The second grant will used for the product development, training and regulatory application required for the microEYE ophthalmic imaging system to be sold in major markets throughout the world. Approvals from the US Food and Drug Administration, the Australian Therapeutic Goods Administration, Japanese Ministry of Health and CE marking in Europe are necessary preconditions for sales and marketing of the microEYE system in the respective countries.

"The awarding of the BDSTS confirms the validity and value of our FunhalerÒ asthma device and microEYE ophthalmic imaging system on a number of levels, primarily enabling us to aggressively pursue the development and commercial potential of our products throughout the world," said Dr William Dolphin, CEO of Visiomed.

The funding is part of the Biotechnology Industry Initiatives Program launched by the former Minister for State Development, Clive Brown in November 2004. The BDSTS is aimed at improving the international competitiveness of Western Australia, by improving the performance of viable businesses within the biotechnology industry. The BDSTS supports a range of services that are used by businesses to enhance performance including skills training, enterprise planning, quality assurance and design consultancy.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->